ANI Pharmaceuticals Q4 Profit $27.5M, Revenues Up 29.6%, Reaffirms FY26 Outlook
ANI Pharmaceuticals reported Q4 net income of $27.49 million ($1.18 per share) versus a year-ago loss of $10.68 million, with revenues up 29.6% to $247.06 million. The company reiterated FY26 guidance for adjusted EPS of $8.83–$9.34 and revenues of $1.055–$1.115 billion.
1. Q4 financial results
ANI Pharmaceuticals swung to a fourth-quarter net income of $27.49 million, or $1.18 per share, compared with a net loss of $10.68 million, or $0.55 per share, in the prior-year quarter. Excluding one-time items, adjusted EPS rose to $2.33 from $1.63, while total net revenues climbed 29.6% to $247.06 million.
2. FY26 guidance reaffirmed
The company maintained its fiscal 2026 outlook, projecting adjusted earnings of $8.83 to $9.34 per share on net revenues between $1.055 billion and $1.115 billion. This guidance range aligns with prior forecasts and reflects confidence in ongoing product demand and operational efficiency.
3. Market reaction
Shares of ANI Pharmaceuticals jumped 7.58% in pre-market trading to $83.00, reflecting investor enthusiasm over the profitability turnaround and confirmation of robust full-year targets.